CNMD — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-04-30

• •compliance with and changes in laws and regulatory requirements;

• •the impact of divestitures of products or product portfolios;

• A significant amount of our products are used in surgical procedures with approximately 85% of our revenues derived from the sale of single-use products. Our capital equipment offerings also facilitate the ongoing sale of related single-use products and accessories, thus providing us with a recurrin…

• In recent years, the Company has experienced higher manufacturing and operating costs as well as ongoing supply chain challenges. We continue to monitor our spending and expenses in light of these factors. We engaged a consulting firm during the past year to evaluate and propose improvements in our …

• On December 5, 2025, we announced our intent to exit our gastroenterology product lines as part of our portfolio optimization strategy. This included the termination of our distribution agreement with W.L. Gore & Associates, Inc. ("Gore") for the Gore® VIABIL® biliary stent effective January 1, 2026…

Text removed vs the prior filing · source: 10-Q · 2025-11-06

• Three Months Ended September 30,Nine Months Ended September 30,

• A significant amount of our products are used in surgical procedures with approximately 86% of our revenues derived from the sale of single-use products. Our capital equipment offerings also facilitate the ongoing sale of related single-use products and accessories, thus providing us with a recurrin…

• The Company has been and continues to be impacted by the macro-economic environment and we are experiencing higher manufacturing and operating costs caused by inflationary pressures and ongoing supply chain challenges. We continue to monitor our spending and expenses in light of these factors. This …

• Under the terms of our Distribution Agreement with W. L. Gore & Associates, Inc. (“Gore®”), CONMED has exclusive distribution rights to the Gore® VIABIL® Biliary Endoprosthesis for endoscopic placement (“VIABIL® device”) in the United States and Canada (“Distribution Agreement”) through December 31,…

• Three Months Ended September 30,Nine Months Ended September 30,

Text added vs the prior filing · source: 10-Q · 2026-04-30

• Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory

• On April 29, 2026, Mr. Andrew Moller, Vice President, Corporate Controller and interim Principal Financial Officer of CONMED Corporation (the “Company”) notified the Company that he will depart the Company effective May 31, 2026 to pursue an opportunity with another company.

• Mr. Moller’s departure did not arise from any disagreement on any matter relating to the operations, policies, financial results or accounting practices of the Company.

• If the Company has not appointed a Chief Financial Officer on or before June 1, 2026, then Mr. Patrick J. Beyer, the Company’s President and Chief Executive Officer has been appointed the Company’s interim Principal Financial Officer following Mr. Moller’s departure and will serve until the Company …

• Biographical information about Mr. Beyer is contained in the Company’s proxy statement for its 2026 annual meeting of stockholders filed with the Securities and Exchange Commission on April 7, 2026.

Text removed vs the prior filing · source: 10-Q · 2025-11-06

• On August 8, 2025, Todd Garner, Executive VP, Finance & CFO, adopted a trading plan with respect to 7,500 restricted stock units granted to Mr. Garner as equity compensation (the "Garner Plan"). The Garner Plan is intended to satisfy the affirmative defense of Rule 10b5-1(c), under the Securities Ex…